Type 2 Diabetes
Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
Can Laser or TENS Therapy Improve Saliva and Oral Bacteria in Type 2 Diabetes?
A very small interim RCT analysis finds laser and TENS to the salivary glands improve flow and shift the oral microbiome in type 2 diabetes, but evidence is preliminary. PICO summary and commentary.
High-Fiber Cereal Improves Liver Fibrosis and Glycemic Control in T2DM with MASLD
An open-label RCT finds 24 g/day fibre cereal improves the FIB-4 fibrosis index and HbA1c in type 2 diabetes with fatty liver, without weight change. PICO summary and commentary.
Does Aquatic Exercise Improve Health in Type 2 Diabetes?
A 5-week RCT finds aquatic exercise improves blood pressure and function within-group in type 2 diabetes, but without significant differences versus controls. PICO summary and commentary.
Can Moxibustion Help Memory in Type 2 Diabetes?
An RCT finds higher-temperature (44-46C) moxibustion improves cognition and HbA1c more than lower temperatures in type 2 diabetes, though fasting glucose was unchanged. PICO summary and commentary.
Exercise Plus Broccoli Sprouts Improves Atherogenic Lipoproteins in Type 2 Diabetes: 12-Week RCT
A four-arm RCT finds exercise plus broccoli sprouts improves apolipoproteins in men with type 2 diabetes, but the benefit is mainly exercise-driven. PICO summary and commentary.
Does Time-Restricted Eating Improve Mood and Quality of Life in Type 2 Diabetes?
A secondary analysis finds neither time-restricted eating nor calorie restriction changes mood or quality of life in type 2 diabetes, suggesting they are psychologically neutral. PICO summary and commentary.
Does Citrulline Improve Blood Flow and Strength in Older Adults with Diabetes?
A small crossover trial finds citrulline improves microvascular function and calf muscle strength in older adults with type 2 diabetes. PICO summary and commentary.
Empagliflozin Alters Plasma Lipidome in Type 2 Diabetes: EmDia Trial Lipidomics Analysis
A lipidomics analysis from the randomised EmDia trial finds empagliflozin remodels plasma lipids in type 2 diabetes, raising beneficial LPCs but also harmful ceramides. PICO summary and commentary.